References
1. Hsu J, Avila PC, Kern RC, Hayes MG, Schleimer RP, Pinto JM. Genetics of chronic rhinosinusitis: state of the field and directions forward.J Allergy Clin Immunol. 2013;131(4):977-993, 993 e971-975.
2. Stevens WW, Lee RJ, Schleimer RP, Cohen NA. Chronic rhinosinusitis pathogenesis. J Allergy Clin Immunol. 2015;136(6):1442-1453.
3. Gudis D, Zhao KQ, Cohen NA. Acquired cilia dysfunction in chronic rhinosinusitis. Am J Rhinol Allergy. 2012;26(1):1-6.
4. Stammberger H, Posawetz W. Functional endoscopic sinus surgery. Concept, indications and results of the Messerklinger technique.Eur Arch Otorhinolaryngol. 1990;247(2):63-76.
5. Song WJ, Lee JH, Won HK, Bachert C. Chronic Rhinosinusitis with Nasal Polyps in Older Adults: Clinical Presentation, Pathophysiology, and Comorbidity. Curr Allergy Asthma Rep. 2019;19(10):46.
6. Chang EH, Stern DA, Willis AL, Guerra S, Wright AL, Martinez FD. Early life risk factors for chronic sinusitis: A longitudinal birth cohort study. J Allergy Clin Immunol. 2018;141(4):1291-1297 e1292.
7. DelGaudio JM, Loftus PA, Hamizan AW, Harvey RJ, Wise SK. Central compartment atopic disease. Am J Rhinol Allergy.2017;31(4):228-234.
8. Bacciu A, Buzio C, Giordano D, et al. Nasal polyposis in Churg-Strauss syndrome. Laryngoscope. 2008;118(2):325-329.
9. Ocampo CJ, Peters AT. Antibody deficiency in chronic rhinosinusitis: epidemiology and burden of illness. Am J Rhinol Allergy.2013;27(1):34-38.
10. Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc. 1999;74(9):877-884.
11. Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001;107(4):607-614.
12. Perloff JR, Palmer JN. Evidence of bacterial biofilms on frontal recess stents in patients with chronic rhinosinusitis. Am J Rhinol. 2004;18(6):377-380.
13. Kern RC, Conley DB, Walsh W, et al. Perspectives on the etiology of chronic rhinosinusitis: an immune barrier hypothesis. Am J Rhinol. 2008;22(6):549-559.
14. Abreu NA, Nagalingam NA, Song Y, et al. Sinus microbiome diversity depletion and Corynebacterium tuberculostearicum enrichment mediates rhinosinusitis. Sci Transl Med. 2012;4(151):151ra124.
15. Tan BK, Lu G, Kwasny MJ, et al. Effect of symptom-based risk stratification on the costs of managing patients with chronic rhinosinusitis symptoms. Int Forum Allergy Rhinol.2013;3(11):933-940.
16. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol.2013;131(6):1479-1490.
17. Harlin SL, Ansel DG, Lane SR, Myers J, Kephart GM, Gleich GJ. A clinical and pathologic study of chronic sinusitis: the role of the eosinophil. J Allergy Clin Immunol. 1988;81(5 Pt 1):867-875.
18. Stoop AE, van der Heijden HA, Biewenga J, van der Baan S. Eosinophils in nasal polyps and nasal mucosa: an immunohistochemical study. J Allergy Clin Immunol. 1993;91(2):616-622.
19. Jankowski R, Bene MC, Moneret-Vautrin AD, et al. Immunohistological characteristics of nasal polyps. A comparison with healthy mucosa and chronic sinusitis. Rhinol Suppl. 1989;8:51-58.
20. Mygind N. Nasal polyposis. J Allergy Clin Immunol. 1990;86(6 Pt 1):827-829.
21. Fokkens WJ, Holm AF, Rijntjes E, Mulder PG, Vroom TM. Characterization and quantification of cellular infiltrates in nasal mucosa of patients with grass pollen allergy, non-allergic patients with nasal polyps and controls. Int Arch Allergy Appl Immunol.1990;93(1):66-72.
22. Drake-Lee A, Price J. Mast cell ultrastructure in the inferior turbinate and stroma of nasal polyps. J Laryngol Otol.1997;111(4):340-345.
23. Polzehl D, Moeller P, Riechelmann H, Perner S. Distinct features of chronic rhinosinusitis with and without nasal polyps. Allergy.2006;61(11):1275-1279.
24. Huvenne W, van Bruaene N, Zhang N, et al. Chronic rhinosinusitis with and without nasal polyps: what is the difference? Curr Allergy Asthma Rep. 2009;9(3):213-220.
25. Sobol SE, Christodoulopoulos P, Manoukian JJ, et al. Cytokine profile of chronic sinusitis in patients with cystic fibrosis.Arch Otolaryngol Head Neck Surg. 2002;128(11):1295-1298.
26. Soler ZM, Sauer D, Mace J, Smith TL. Impact of mucosal eosinophilia and nasal polyposis on quality-of-life outcomes after sinus surgery.Otolaryngol Head Neck Surg. 2010;142(1):64-71.
27. Stierna P, Carlsoo B. Histopathological observations in chronic maxillary sinusitis. Acta Otolaryngol. 1990;110(5-6):450-458.
28. Berger G, Kattan A, Bernheim J, Ophir D. Polypoid mucosa with eosinophilia and glandular hyperplasia in chronic sinusitis: a histopathological and immunohistochemical study. Laryngoscope.2002;112(4):738-745.
29. Malekzadeh S, McGuire JF. The new histologic classification of chronic rhinosinusitis. Curr Allergy Asthma Rep.2003;3(3):221-226.
30. Kuhar HN, Tajudeen BA, Heilingoetter A, et al. Distinct histopathologic features of radiation-induced chronic sinusitis.Int Forum Allergy Rhinol. 2017;7(10):990-998.
31. Brescia G, Alessandrini L, Marioni G. Structured histopathology for endotyping and planning rational treatment in chronic rhinosinusitis.Am J Otolaryngol. 2021;42(1):102795.
32. Takabayashi T, Kato A, Peters AT, et al. Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. Am J Respir Crit Care Med. 2013;187(1):49-57.
33. Takabayashi T, Kato A, Peters AT, et al. Increased expression of factor XIII-A in patients with chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2013.
34. Chen CL, Yao Y, Pan L, et al. Common fibrin deposition and tissue plasminogen activator downregulation in nasal polyps with distinct inflammatory endotypes. J Allergy Clin Immunol.2020;146(3):677-681.
35. Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol.1997;99(6 Pt 1):837-842.
36. Bachert C, Wagenmann M, Rudack C, et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy.1998;53(1):2-13.
37. Takeuchi K, Yuta A, Sakakura Y. Interleukin-8 gene expression in chronic sinusitis. Am J Otolaryngol. 1995;16(2):98-102.
38. Suzuki H, Takahashi Y, Wataya H, et al. Mechanism of neutrophil recruitment induced by IL-8 in chronic sinusitis. J Allergy Clin Immunol. 1996;98(3):659-670.
39. Riechelmann H, Deutschle T, Rozsasi A, Keck T, Polzehl D, Burner H. Nasal biomarker profiles in acute and chronic rhinosinusitis. Clin Exp Allergy. 2005;35(9):1186-1191.
40. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy.2006;61(11):1280-1289.
41. Cao PP, Li HB, Wang BF, et al. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol. 2009;124(3):478-484, 484 e471-472.
42. Zhang N, Van Zele T, Perez-Novo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol. 2008;122(5):961-968.
43. Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers.J Allergy Clin Immunol. 2016;137(5):1449-1456 e1444.
44. Bachert C, Akdis CA. Phenotypes and Emerging Endotypes of Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):621-628.
45. Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015;64(2):121-130.
46. Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev Pathol. 2017;12:331-357.
47. Peterson S, Poposki JA, Nagarkar DR, et al. Increased expression of CC chemokine ligand 18 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2012;129(1):119-127 e111-119.
48. Takabayashi T, Kato A, Peters AT, et al. Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2012;130(2):410-420 e415.
49. Hulse KE, Norton JE, Suh L, et al. Chronic rhinosinusitis with nasal polyps is characterized by B-cell inflammation and EBV-induced protein 2 expression. J Allergy Clin Immunol. 2013;131(4):1075-1083, 1083 e1071-1077.
50. Derycke L, Eyerich S, Van Crombruggen K, et al. Mixed T helper cell signatures in chronic rhinosinusitis with and without polyps. PLoS One. 2014;9(6):e97581.
51. Mahdavinia M, Carter RG, Ocampo CJ, et al. Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity. J Allergy Clin Immunol. 2014;133(6):1759-1763.
52. Shi LL, Song J, Xiong P, et al. Disease-specific T-helper cell polarizing function of lesional dendritic cells in different types of chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med. 2014;190(6):628-638.
53. Poposki JA, Peterson S, Welch K, et al. Elevated presence of myeloid dendritic cells in nasal polyps of patients with chronic rhinosinusitis.Clin Exp Allergy. 2015;45(2):384-393.
54. Poposki JA, Klingler AI, Tan BK, et al. Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps. Immun Inflamm Dis. 2017;5(3):233-243.
55. Klingler AI, Stevens WW, Tan BK, et al. Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps.J Allergy Clin Immunol. 2020.
56. Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344-1353.
57. Tan BK, Klingler AI, Poposki JA, et al. Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. J Allergy Clin Immunol. 2017;139(2):699-703 e697.
58. Stevens WW, Peters AT, Tan BK, et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812-2820 e2813.
59. Baba S, Kondo K, Toma-Hirano M, et al. Local increase in IgE and class switch recombination to IgE in nasal polyps in chronic rhinosinusitis. Clin Exp Allergy. 2014;44(5):701-712.
60. Plager DA, Kahl JC, Asmann YW, et al. Gene transcription changes in asthmatic chronic rhinosinusitis with nasal polyps and comparison to those in atopic dermatitis. PLoS One. 2010;5(7):e11450.
61. Tyler MA, Russell CB, Smith DE, et al. Large-scale gene expression profiling reveals distinct type 2 inflammatory patterns in chronic rhinosinusitis subtypes. J Allergy Clin Immunol.2017;139(3):1061-1064 e1064.
62. Wang W, Gao Z, Wang H, et al. Transcriptome Analysis Reveals Distinct Gene Expression Profiles in Eosinophilic and Noneosinophilic Chronic Rhinosinusitis with Nasal Polyps. Sci Rep. 2016;6:26604.
63. Okada N, Nakayama T, Asaka D, et al. Distinct gene expression profiles and regulation networks of nasal polyps in eosinophilic and non-eosinophilic chronic rhinosinusitis. Int Forum Allergy Rhinol. 2018;8(5):592-604.
64. Ryu G, Mo JH, Shin HW. Epithelial-to-mesenchymal transition in neutrophilic chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. 2021;21(1):30-37.
65. Seshadri S, Rosati M, Lin DC, et al. Regional differences in the expression of innate host defense molecules in sinonasal mucosa. J Allergy Clin Immunol. 2013;132(5):1227-1230 e1225.
66. Wen W, Liu W, Zhang L, et al. Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy. J Allergy Clin Immunol. 2012;129(6):1522-1528 e1525.
67. Katotomichelakis M, Tantilipikorn P, Holtappels G, et al. Inflammatory patterns in upper airway disease in the same geographical area may change over time. Am J Rhinol Allergy.2013;27(5):354-360.
68. Kim SJ, Lee KH, Kim SW, Cho JS, Park YK, Shin SY. Changes in histological features of nasal polyps in a Korean population over a 17-year period. Otolaryngol Head Neck Surg. 2013;149(3):431-437.
69. Delemarre T, Holtappels G, De Ruyck N, et al. A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020.
70. Delemarre T, Holtappels G, De Ruyck N, et al. Type 2 inflammation in chronic rhinosinusitis without nasal polyps: Another relevant endotype.J Allergy Clin Immunol. 2020;146(2):337-343 e336.
71. Van Zele T, Gevaert P, Holtappels G, van Cauwenberge P, Bachert C. Local immunoglobulin production in nasal polyposis is modulated by superantigens. Clin Exp Allergy. 2007;37(12):1840-1847.
72. Buchheit KM, Dwyer DF, Ordovas-Montanes J, et al. IL-5Ralpha marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol.2020;145(6):1574-1584.
73. Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;132(3):593-600 e512.
74. Liu T, Li TL, Zhao F, et al. Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis. Am J Med Sci.2011;341(1):40-47.
75. Boita M, Garzaro M, Raimondo L, et al. Eosinophilic inflammation of chronic rhinosinusitis with nasal polyps is related to OX40 ligand expression. Innate Immun. 2015;21(2):167-174.
76. Ogasawara N, Klingler AI, Tan BK, et al. Epithelial activators of type 2 inflammation: Elevation of thymic stromal lymphopoietin, but not IL-25 or IL-33, in chronic rhinosinusitis with nasal polyps in Chicago, Illinois. Allergy. 2018;73(11):2251-2254.
77. Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease. Am J Respir Crit Care Med. 2015;192(6):682-694.
78. Takabayashi T, Schleimer RP. Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin. J Allergy Clin Immunol. 2020;145(3):740-750.
79. Feldman S, Kasjanski R, Poposki J, et al. Chronic airway inflammation provides a unique environment for B cell activation and antibody production. Clin Exp Allergy. 2017;47(4):457-466.
80. Van Bruaene N, Perez-Novo CA, Basinski TM, et al. T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol.2008;121(6):1435-1441, 1441 e1431-1433.
81. Pinu FR, Beale DJ, Paten AM, et al. Systems Biology and Multi-Omics Integration: Viewpoints from the Metabolomics Research Community.Metabolites. 2019;9(4).
82. Veenstra TD. Systems Biology: Current Progress and Future Outlook.Proteomics. 2020:e2000235.
83. Michalik M, Samet A, Dmowska-Koroblewska A, et al. An Overview of the Application of Systems Biology in an Understanding of Chronic Rhinosinusitis (CRS) Development. J Pers Med. 2020;10(4).
84. Kao SS, Bassiouni A, Ramezanpour M, et al. Scoping review of chronic rhinosinusitis proteomics. Rhinology. 2020;58(5):418-429.
85. Kao SS, Bassiouni A, Ramezanpour M, et al. Proteomic analysis of nasal mucus samples of healthy patients and patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2021;147(1):168-178.
86. Fazlollahi F, Kongmanas K, Tanphaichitr N, et al. Lipidomic profiling of sinus mucosa from patients with chronic rhinosinusitis.Clin Transl Sci. 2015;8(2):107-115.
87. Miyata J, Fukunaga K, Kawashima Y, et al. Dysregulated fatty acid metabolism in nasal polyp-derived eosinophils from patients with chronic rhinosinusitis. Allergy. 2019;74(6):1113-1124.
88. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol.2015;135(3):676-681 e671.
89. Stevens WW, Peters AT, Hirsch AG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2017;5(4):1061-1070 e1063.
90. White AA, Stevenson DD. Aspirin-Exacerbated Respiratory Disease.N Engl J Med. 2018;379(11):1060-1070.
91. Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.Allergy. 2019;74(1):28-39.
92. Stevens WW, Jerschow E, Baptist AP, et al. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2020.
93. Scott WC, Cahill KN, Milne GL, et al. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol.2020.
94. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650.
95. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595-605.
96. Laidlaw TM, Mullol J, Fan C, et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract. 2019;7(7):2462-2465 e2461.
97. Jakiela B, Soja J, Sladek K, et al. Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease.J Allergy Clin Immunol. 2020.
98. Laidlaw TM, Boyce JA. Aspirin-Exacerbated Respiratory Disease–New Prime Suspects. N Engl J Med. 2016;374(5):484-488.
99. Stevens WW, Staudacher AG, Hulse KE, et al. Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease.J Allergy Clin Immunol. 2021;147(2):600-612.
100. Kristjansson RP, Benonisdottir S, Davidsson OB, et al. A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis. Nat Genet. 2019;51(2):267-276.
101. Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135(1):245-252.
102. Wang M, Bu X, Luan G, et al. Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma. Clin Transl Allergy. 2020;10:26.
103. Szucs E, Ravandi S, Goossens A, Beel M, Clement PA. Eosinophilia in the ethmoid mucosa and its relationship to the severity of inflammation in chronic rhinosinusitis. Am J Rhinol. 2002;16(3):131-134.
104. Kountakis SE, Arango P, Bradley D, Wade ZK, Borish L. Molecular and cellular staging for the severity of chronic rhinosinusitis.Laryngoscope. 2004;114(11):1895-1905.
105. Morse JC, Li P, Ely KA, et al. Chronic rhinosinusitis in elderly patients is associated with an exaggerated neutrophilic proinflammatory response to pathogenic bacteria. J Allergy Clin Immunol.2019;143(3):990-1002 e1006.
106. Van Zele T, Gevaert P, Watelet JB, et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol. 2004;114(4):981-983.
107. Tripathi A, Kern R, Conley DB, et al. Staphylococcal exotoxins and nasal polyposis: analysis of systemic and local responses. Am J Rhinol. 2005;19(4):327-333.
108. Bachert C, Zhang N, Holtappels G, et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol.2010;126(5):962-968, 968 e961-966.
109. Jonstam K, Westman M, Holtappels G, Holweg CTJ, Bachert C. Serum periostin, IgE, and SE-IgE can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017;140(6):1705-1708 e1703.
110. Soler ZM, Oyer SL, Kern RC, et al. Antimicrobials and chronic rhinosinusitis with or without polyposis in adults: an evidenced-based review with recommendations. Int Forum Allergy Rhinol.2013;3(1):31-47.
111. Smith SS, Evans CT, Tan BK, Chandra RK, Smith SB, Kern RC. National burden of antibiotic use for adult rhinosinusitis. J Allergy Clin Immunol. 2013;132(5):1230-1232.
112. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.
113. Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213-739.
114. Gunel C, Bleier BS, Meteoglu I. Antibiotics in eosinophilic chronic rhinosinusitis: Rethinking maximal antimicrobial medical therapy.Laryngoscope. 2017;127(4):794-796.
115. Bachert C, Gevaert P, Zhang N, van Zele T, Perez-Novo C. Role of staphylococcal superantigens in airway disease. Chem Immunol Allergy. 2007;93:214-236.
116. Lan F, Zhang N, Holtappels G, et al. Staphylococcus aureus Induces a Mucosal Type 2 Immune Response via Epithelial Cell-derived Cytokines.Am J Respir Crit Care Med. 2018;198(4):452-463.
117. Bachert C, Holtappels G, Merabishvili M, et al. Staphylococcus aureus controls interleukin-5 release in upper airway inflammation.J Proteomics. 2018;180:53-60.
118. Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients.Tohoku J Exp Med. 1997;182(2):115-124.
119. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429(1-3):209-229.
120. Healy DP. Macrolide immunomodulation of chronic respiratory diseases. Curr Infect Dis Rep. 2007;9(1):7-13.
121. Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope.2006;116(2):189-193.
122. Videler WJ, Badia L, Harvey RJ, et al. Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized controlled trial. Allergy. 2011;66(11):1457-1468.
123. Haruna S, Shimada C, Ozawa M, Fukami S, Moriyama H. A study of poor responders for long-term, low-dose macrolide administration for chronic sinusitis. Rhinology. 2009;47(1):66-71.
124. Bezerra TFP, Pezato R, de Barros PM, et al. Prospective evaluation of clarithromycin in recurrent chronic rhinosinusitis with nasal polyps.Braz J Otorhinolaryngol. 2019.
125. Huang Z, Zhou B. Clarithromycin for the treatment of adult chronic rhinosinusitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2019;9(5):545-555.
126. Oakley GM, Harvey RJ, Lund VJ. The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP). Curr Allergy Asthma Rep.2017;17(5):30.
127. Seresirikachorn K, Suwanparin N, Srisunthornphanich C, Chitsuthipakorn W, Kanjanawasee D, Snidvongs K. Factors of success of low-dose macrolides in chronic sinusitis: Systematic review and meta-analysis. Laryngoscope. 2019;129(7):1510-1519.
128. Lees KA, Orlandi RR, Oakley G, Alt JA. The Role of Macrolides and Doxycycline in Chronic Rhinosinusitis. Immunol Allergy Clin North Am. 2020;40(2):303-315.
129. Henehan M, Montuno M, De Benedetto A. Doxycycline as an anti-inflammatory agent: updates in dermatology. J Eur Acad Dermatol Venereol. 2017;31(11):1800-1808.
130. Gueders MM, Bertholet P, Perin F, et al. A novel formulation of inhaled doxycycline reduces allergen-induced inflammation, hyperresponsiveness and remodeling by matrix metalloproteinases and cytokines modulation in a mouse model of asthma. Biochem Pharmacol. 2008;75(2):514-526.
131. Kuzin, II, Snyder JE, Ugine GD, et al. Tetracyclines inhibit activated B cell function. Int Immunol. 2001;13(7):921-931.
132. Van Zele T, Gevaert P, Holtappels G, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069-1076 e1064.
133. De Schryver E, Derycke L, Calus L, et al. The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps.Rhinology. 2017;55(2):152-160.
134. Grammer LC. Doxycycline or oral corticosteroids for nasal polyps.J Allergy Clin Immunol Pract. 2013;1(5):541-542.
135. Cardell LO, Stjarne P, Jonstam K, Bachert C. Endotypes of chronic rhinosinusitis: Impact on management. J Allergy Clin Immunol.2020;145(3):752-756.
136. Pinto Bezerra Soter AC, Bezerra TF, Pezato R, et al. Prospective open-label evaluation of long-term low-dose doxycycline for difficult-to-treat chronic rhinosinusitis with nasal polyps.Rhinology. 2017;55(2):175-180.
137. Sommer JU, Schultz JD, Grossbaier J, Stern-Straeter J, Hormann K, Sauter A. In vitro effects of doxycycline on inflammatory cytokines and gelatinases in chronic rhinosinusitis. In Vivo.2012;26(3):369-374.
138. Banuelos J, Lu NZ. A gradient of glucocorticoid sensitivity among helper T cell cytokines. Cytokine Growth Factor Rev.2016;31:27-35.
139. Raundhal M, Morse C, Khare A, et al. High IFN-gamma and low SLPI mark severe asthma in mice and humans. J Clin Invest.2015;125(8):3037-3050.
140. Halwani R, Al-Muhsen S, Hamid Q. T helper 17 cells in airway diseases: from laboratory bench to bedside. Chest.2013;143(2):494-501.
141. Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System. Front Immunol. 2019;10:1744.
142. Belvisi MG. Regulation of inflammatory cell function by corticosteroids. Proc Am Thorac Soc. 2004;1(3):207-214.
143. Walford HH, Lund SJ, Baum RE, et al. Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness. Clin Immunol. 2014;155(1):126-135.
144. Doherty TA, Broide DH. Pathways to limit group 2 innate lymphoid cell activation. J Allergy Clin Immunol. 2017;139(5):1465-1467.
145. Ogasawara N, Poposki JA, Klingler AI, et al. IL-10, TGF-beta, and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells. J Allergy Clin Immunol.2018;141(3):1147-1151 e1148.
146. Schleimer RP, Freeland HS, Peters SP, Brown KE, Derse CP. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. J Pharmacol Exp Ther.1989;250(2):598-605.
147. Ray A, Kolls JK. Neutrophilic Inflammation in Asthma and Association with Disease Severity. Trends Immunol.2017;38(12):942-954.
148. Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Different types of intranasal steroids for chronic rhinosinusitis.Cochrane Database Syst Rev. 2016;4:CD011993.
149. Kalish L, Snidvongs K, Sivasubramaniam R, Cope D, Harvey RJ. Topical steroids for nasal polyps. Cochrane Database Syst Rev.2012;12:CD006549.
150. Head K, Chong LY, Piromchai P, et al. Systemic and topical antibiotics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011994.
151. Zhou B, He G, Liang J, et al. Mometasone furoate nasal spray in the treatment of nasal polyposis in Chinese patients: a double-blind, randomized, placebo-controlled trial. Int Forum Allergy Rhinol.2016;6(1):88-94.
152. Hissaria P, Smith W, Wormald PJ, et al. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol. 2006;118(1):128-133.
153. Britt RD, Jr., Thompson MA, Sasse S, Pabelick CM, Gerber AN, Prakash YS. Th1 cytokines TNF-alpha and IFN-gamma promote corticosteroid resistance in developing human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2019;316(1):L71-L81.
154. Nabe T. Steroid-Resistant Asthma and Neutrophils. Biol Pharm Bull. 2020;43(1):31-35.
155. Harvey RJ, Snidvongs K, Kalish LH, Oakley GM, Sacks R. Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery. Int Forum Allergy Rhinol.2018;8(4):461-470.
156. Kern RC, Stolovitzky JP, Silvers SL, et al. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol. 2018;8(4):471-481.
157. Djupesland PG, Skretting A, Winderen M, Holand T. Breath actuated device improves delivery to target sites beyond the nasal valve.Laryngoscope. 2006;116(3):466-472.
158. Fokkens W, Reitsma S. New delivery forms of nasal corticosteroids.J Allergy Clin Immunol. 2019;143(1):87-88.
159. Tait S, Kallogjeri D, Suko J, Kukuljan S, Schneider J, Piccirillo JF. Effect of Budesonide Added to Large-Volume, Low-pressure Saline Sinus Irrigation for Chronic Rhinosinusitis: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2018;144(7):605-612.
160. Leopold DA, Elkayam D, Messina JC, Kosik-Gonzalez C, Djupesland PG, Mahmoud RA. NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol. 2019;143(1):126-134 e125.
161. Sekiyama A, Gon Y, Terakado M, et al. Glucocorticoids enhance airway epithelial barrier integrity. Int Immunopharmacol.2012;12(2):350-357.
162. Steelant B, Farre R, Wawrzyniak P, et al. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression.J Allergy Clin Immunol. 2016;137(4):1043-1053 e1045.
163. Ordovas-Montanes J, Dwyer DF, Nyquist SK, et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells.Nature. 2018;560(7720):649-654.
164. Corren J. New Targeted Therapies for Uncontrolled Asthma. J Allergy Clin Immunol Pract. 2019;7(5):1394-1403.
165. Ghogomu N, Kern R. Chronic rhinosinusitis: the rationale for current treatments. Expert Rev Clin Immunol. 2017;13(3):259-270.
166. Chin D, Harvey RJ. Nasal polyposis: an inflammatory condition requiring effective anti-inflammatory treatment. Curr Opin Otolaryngol Head Neck Surg. 2013;21(1):23-30.
167. Chandra RK, Kern RC, Cutler JL, Welch KC, Russell PT. REMODEL larger cohort with long-term outcomes and meta-analysis of standalone balloon dilation studies. Laryngoscope. 2016;126(1):44-50.
168. Leung RM, Kern RC, Conley DB, Tan BK, Chandra RK. Osteomeatal complex obstruction is not associated with adjacent sinus disease in chronic rhinosinusitis with polyps. Am J Rhinol Allergy.2011;25(6):401-403.
169. Snidvongs K, Kalish L, Sacks R, Sivasubramaniam R, Cope D, Harvey RJ. Sinus surgery and delivery method influence the effectiveness of topical corticosteroids for chronic rhinosinusitis: systematic review and meta-analysis. Am J Rhinol Allergy. 2013;27(3):221-233.
170. DeConde AS, Smith TL. Outcomes After Frontal Sinus Surgery: An Evidence-Based Review. Otolaryngol Clin North Am.2016;49(4):1019-1033.
171. Snidvongs K, Pratt E, Chin D, Sacks R, Earls P, Harvey RJ. Corticosteroid nasal irrigations after endoscopic sinus surgery in the management of chronic rhinosinusitis. Int Forum Allergy Rhinol.2012;2(5):415-421.
172. Bassiouni A, Ou J, Rajiv S, Cantero D, Vreugde S, Wormald PJ. Subepithelial inflammatory load and basement membrane thickening in refractory chronic rhinosinusitis with nasal polyposis: a histopathological study. Int Forum Allergy Rhinol.2016;6(3):248-255.
173. Jankowski R, Bodino C. Evolution of symptoms associated to nasal polyposis following oral steroid treatment and nasalization of the ethmoid–radical ethmoidectomy is functional surgery for NPS.Rhinology. 2003;41(4):211-219.
174. Barham HP, Ramakrishnan VR, Knisely A, et al. Frontal sinus surgery and sinus distribution of nasal irrigation. Int Forum Allergy Rhinol. 2016;6(3):238-242.
175. Alsharif S, Jonstam K, van Zele T, Gevaert P, Holtappels G, Bachert C. Endoscopic Sinus Surgery for Type-2 CRS wNP: An Endotype-Based Retrospective Study. Laryngoscope. 2019;129(6):1286-1292.
176. Morrissey DK, Bassiouni A, Psaltis AJ, Naidoo Y, Wormald PJ. Outcomes of modified endoscopic Lothrop in aspirin-exacerbated respiratory disease with nasal polyposis. Int Forum Allergy Rhinol. 2016;6(8):820-825.
177. Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy.2014;28(3):192-198.
178. Lou H, Fang J, Li P, et al. Frequency, suppressive capacity, recruitment and induction mechanisms of regulatory T cells in sinonasal squamous cell carcinoma and nasal inverted papilloma. PLoS One.2015;10(5):e0126463.
179. Tokunaga T, Sakashita M, Haruna T, et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study.Allergy. 2015;70(8):995-1003.
180. Khairuddin NK, Salina H, Gendeh BS, Wan Hamizan AK, Lund VJ. Quality of life and recurrence of disease in patients with eosinophilic and non-eosinophilic 1 chronic rhinosinusitis with nasal polyposis.Med J Malaysia. 2018;73(1):1-6.
181. Rosati D, Rosato C, Pagliuca G, et al. Predictive markers of long-term recurrence in chronic rhinosinusitis with nasal polyps.Am J Otolaryngol. 2020;41(1):102286.
182. Pan L, Liao B, Guo CL, et al. Inflammatory features and predictors for postsurgical outcomes in patients with nasal polyps stratified by local and systemic eosinophilia. Int Forum Allergy Rhinol. 2020.
183. Ryu G, Kim DK, Dhong HJ, et al. Immunological Characteristics in Refractory Chronic Rhinosinusitis with Nasal Polyps Undergoing Revision Surgeries. Allergy Asthma Immunol Res. 2019;11(5):664-676.
184. Bachert C, Mannent L, Naclerio RM, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA.2016;315(5):469-479.
185. Chang TW, Davis FM, Sun NC, Sun CR, MacGlashan DW, Jr., Hamilton RG. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases.Biotechnology (N Y). 1990;8(2):122-126.
186. Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2021;147(1):29-36.
187. Hopkins C, Slack R, Lund V, Brown P, Copley L, Browne J. Long-term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Laryngoscope.2009;119(12):2459-2465.
188. Smith TL, Schlosser RJ, Mace JC, et al. Long-term outcomes of endoscopic sinus surgery in the management of adult chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019;9(8):831-841.
189. Smith KA, Orlandi RR, Oakley G, Meeks H, Curtin K, Alt JA. Long-term revision rates for endoscopic sinus surgery. Int Forum Allergy Rhinol. 2019;9(4):402-408.